A further randomized phase II study compared pembrolizumab single agent to pembrolizumab plus vorinostat in non-pretreated metastatic NSCLC patients with PD-L1 expression TPS > 1% [42]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.